Powered by

City of Hope Enters Licensing Agreements with CytoImmune Therapeutics Inc. to Develop Portfolio of Chimeric Antigen Receptor-Natural Killer Therapies; License and development agreements will advance several immunotherapies

Apr 08, 2021 - Business Wire

City of Hope , a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and CytoImmune Therapeutics Inc. ("CytoImmune"), a clinical-stage biopharmaceutical company focused on commercializing novel cancer immunotherapy products, announced that they have entered into worldwide exclusive license agreements.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210408005072/en/

City of Hope and CytoImmune Therapeutics Inc. have entered into worldwide exclusive license agreements to several patent applications related to methods to generate large numbers of fully functional natural killer (NK) cells derived from umbilical cord blood and compositions of chimeric receptors (CAR) for targeting NK cells to tumors. (Photo: CytoImmune Therapeutics I...